Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 180 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Follow-Up Questions
BPMUF hissesinin fiyat performansı nasıl?
BPMUF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Basilea Pharmaceutica AG Allschwil için ana iş temaları veya sektörler nelerdir?
Basilea Pharmaceutica AG Allschwil Biotechnology endüstrisine ait ve sektör Health Care 'dir
Basilea Pharmaceutica AG Allschwil 'in piyasa değerlemesi nedir?
Basilea Pharmaceutica AG Allschwil 'in mevcut piyasa değerlemesi $0 'dir
Basilea Pharmaceutica AG Allschwil al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 9 analist Basilea Pharmaceutica AG Allschwil için analist derecelendirmeleri gerçekleştirdi, bunlar 4 güçlü al, 5 al, 2 tut, 0 sat ve 4 güçlü sat içermektedir
